- Smeele Kirsten M. A., Southworth Richard, Wu Rongxue, Xie Chaoqin, Nederlof Rianne, Warley Alice, Nelson Jessica K., van Horssen Pepijn, van den Wijngaard Jeroen P., Heikkinen Sami, Laakso Markku, Koeman Anneke, Siebes Maria, Eerbeek Otto, Akar Fadi G., Ardehali Hossein, Hollmann Markus W., Zuurbier Coert J. Disruption of Hexokinase II-Mitochondrial Binding Blocks Ischemic Preconditioning and Causes Rapid Cardiac Necrosis Circulation research 2011;108 (10):1165-9 [PubMed]
- Wu Rongxue, Smeele Kirsten M., Wyatt Eugene, Ichikawa Yoshihiko, Eerbeek Otto, Sun Lin, Chawla Kusum, Hollmann Markus W., Nagpal Varun, Heikkinen Sami, Laakso Markku, Jujo Kentaro, Wasserstrom J. Andrew, Zuurbier Coert J., Ardehali Hossein Reduction in Hexokinase II Levels Results in Decreased Cardiac Function and Altered Remodeling After Ischemia/Reperfusion Injury Circulation research 2011;108 (1):60-U128 [PubMed]
- Nederlof Rianne, Xie Chaoqin, Eerbeek Otto, Koeman Anneke, Milstein Dan M. J., Hollmann Markus W., Mik Egbert G., Warley Alice, Southworth Richard, Akar Fadi G., Zuurbier Coert J. Pathophysiological consequences of TAT-HKII peptide administration are independent of impaired vascular function and ensuing ischemia Circulation research 2013;112 (2):e8-13 [PubMed]
- Nederlof Rianne, Eerbeek Otto, Hollmann Markus W., Southworth Richard, Zuurbier Coert J. Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart British journal of pharmacology 2014;171 (8):2067-2079 [PubMed]
- Baartscheer Antonius, Schumacher Cees A., Wüst Rob C. I., Fiolet Jan W. T., Stienen Ger J. M., Coronel Ruben, Zuurbier Coert J. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits Diabetologia 2017;60 (3):568-573 [PubMed]
C.J. Zuurbier MEng PhD (Cell survival mechanisms in acute and chronic cardiovascular pathology)
1) EXPLORING CANCER'S RESISTANCE AGAINST CELL DEATH TO FIGHT HEART DISEASE
The role of the glycolytic enzyme hexokinase and its binding to mitochondria in cell death in healthy, diabetic, remodelled and I/R hearts is investigated.
The underlying hypothesis is that our main energy factory, the mitochondrion, a proto-bacterium that invaded the eukaryotic cell about 2 miljard years ago, is kept in check by a protein hexokinase, that belongs to the pre-exisitng energy production pathway, the glycolysis. It is now clear that many forms of cell death are initiated by the mitochondrion, and that hexokinase may be viewed as a gatekeeper of this important energy / dead factory. Part of the resistance of cancer cell against cell death is probably due to its high (> 10 x) expression of hexokinase bound to mitochondria. We were the first to show that this protective mechanism may also be explored for the heart. In this project we explore whether ther heart can also use this protective mechanism against cell death, and whether pathologies with increased incidence of cardiac diseases can be traced down to diminished amounts of hexokinase (diabetes, heart failure, unprotected hearts)
Collaboration: dr Rick Southworth, King's College London; dr Fadi Akar & dr C. Xie, Mount Sinai Medical Center, New York; dr Hossein Ardehali & dr R Wu, Northwestern University, Chicago; dr Otto Eerbeek, department Physiology, AMC
2) DIABETES AND HEART FAILURE: AMPLIFICATION THROUGH SIMILAR UNDERLYING IONIC DISTURBANCES
Diabetic patients have a 3-4 higher risk for cardiovascular diseases as non-diabetic patients. Here we explore the cellualr mechanisms for this interactions. We were able to unravel one of the underlying mechanism of the first diabetes drug class (SGLT2 inhibitors) able to reduce cardiovascular diseases in diabetes and build on this discoveries by focussing on the detrimental role of glucose and sodium in the pathology of both diabetes and heart failure.
Collaboration: dr Ruben Coronel, dr A baartscheer, dr J Fiolet, C Schumacher, department Cardiology, AMC
3) THE ROLE OF INNATE IMMUNITY IN CARDIAC INFARCT DEVELOPMENT
Inflammation and ischemie-reperfusie injury often have similar celluar trigger and effector mechanisms. In this project we examine whether and how our innate immune system (NLRP3, NLRX1) affects cardiac ischemia-reperfusion and the involvement of cardiac metabolism in these processes.
collaboration; dr Jaklien Leemans, department of Pathology
4) The interaction between ANESTHESIA, METABOLISM and INFLAMMATION; Optimizing Anesthesia for Animal Research
Usually, the anesthesiologist works in separate fields as the endocrinologist or the internist. However, as always, it all interacts. In this reseach line we examine how different anesthetic regimens affect metabolic (glucose, insulin, FFA) and inflammatory parameters. Our final goal is to optimize anesthetic regimens to allow high-quality animal research, with important spin-offs to the clinical arena.
Collaboration: dr W. Florijn, DEC, AMC, Diane Bakker, dr. S Houten, Lab. Genetic Metabolic Diseases
D. Bakker BSc
A. van Galen
Prof. M.J. Schultz MD PhD (Prevention and treatment of organ failure in intensive care medicine)
Prof. M.W. Hollmann MD PhD (Organprotection)
J. Horn MD PhD (Neurology on the Intensive Care Unit)
Prof. N.P. Juffermans MD PhD (Pathogenesis and treatment of organ failure in the critically ill)
Prof. B. Preckel MA MD PhD (Patient safety, procedural sedation, cardiovascular protection, optimizing perioperative metabolism, cerebral perfusion, Wireless Monitoring)
- Boehringer Ingelheim International GmbH
- European Foundation for the Study of Diabetes